Molecular Pharmacology Limited (PK) (MLPH) News

Quarterly posted to IQ yesterday. They seem to think they can get CE off, if not why waste time and money filing.

With a skull…lol

Expert Market to Pink Limited today

Looks like someone trying to get this trading again. If they get CE gone, it will fly

Annual filed!

CE Removal candidate?

MLPH SEC Suspension because of questions regarding the adequacy and accuracy of information about the company.

https://www.sec.gov/litigation/suspensions/2021/34-91170.pdf

Order:

https://www.sec.gov/litigation/suspensions/2021/34-91170-o.pdf

You got that right!

I have a ..... dun dun dun dun ........ 1000 shares (one thousand shares) from a partial fill long ago subpenny. Was hard to get shares and they went dark so I gave up. nice move today but no opportunity for anyone to have any shares!!!

~ Pump And Dump ~ Beware :)

Promo pump and then dump, once the front runners start hitting the bids.

Some movers this week!

and Orbitstocks as well put out an e-mail. although a bit late to get in for most

Penny stock spy.
Wolf of penny stocks
Epic stock picks

All the same people, but penny stock spy promoter it. He promoted RLIA which was over 300% this one might do it as well, its just hard to catch the meet of the move.

Already up 180%....what's going on with MLPH?

ANOTHER OTC POS gone dark(unregistered, non-reporting)

Interesting HDOGTX!

MLPH 15-12g

http://archive.fast-edgar.com//20150305/AM29R22CR222N2Z2222D22DZV232Z2G24272/

Wow this be a risky buy but cheap as it MIGHT get?
Thx Ore!

Things haven't worked out they way I expected. Parent company having some issues with their debt holders. 10q next month hopefully will have some new info

I suspect my investment in MLPH is worthless and information is lacking. Anyone richard@richrodriguezcpa.com

Excitement here today at MLPH may have to do with the recent news from the parent company that they are in advanced discussions with a "multinational" corporation concerning a "materials transfer agreement" for their patented Nutracel products

MLPH is up by 100%

What would a company be worth if it's line of already developed, different, patented, proven skin care and pain relief products were launched in this country, backed by the endorsement of a world-famous dermatologist? Hard to say; it depends on availability and subsequent volume, but what if the products were rolled out at Walgreens at it's 7000+ stores? MLPH would be worth considerably more than it's current $2 million market cap. Have you checked their financials? Way more liabilities than assets but the liabilities are monies advanced by the parent company and not the typical toxic financing you see in penny stocks so I'm not worried about that. With a very low effective O/S count (80% owned by the parent company, Pharmanet), we'll have a flyer here when product launch is announced. Latest info from the parent company is that "leads are being followed up." The leads are from Dr. Perry Robins' Dermatology Development Corporation (DDC) discussions with "third parties." What makes this special is that neither DDC nor MLPH has to come up with any major money to develop, manufacture, or roll out the products. The way the deal is structured DDC will get royalties from sales. All that has to happen is for the "third parties" to agree to order and sell the products, which already exist.

Nice close today. Hopefully it holds up.

.025 X ,03 with a close of .03

What's coming to MLPH:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92352038

MLPH company profile updated at Bloomberg/Business Week. Deal with DDC added

Shares Outstanding 111,553,740 a/o Aug 13, 2013
79% of O/S held by Pharmanet
There's no convertible debt or preferred stock.

DDC (Dermatology Development Corporation) owned by Perry Robins, MD. His stamp of approval on ThermaLIFE products bodes well for the future. Imo, of course :)

Perry Robins, MD:

http://www.skincancer.org/about-us/who-we-are/dr-perry-robins

From Bloomberg/Business Week:

"Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain, and is available in various dosage forms, formulations, line extensions, and package configurations. It focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. The company also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited."

A patience play

This could be getting very hott, if and once a major player steps into the ring.

Understood, just dabbled a little can always add more later, bank acct, play, let it grow on it's own

Welcome. Patience play

Joined here today at 017 MLPH

There was a one day p&d promo here in June of 2012. Company was not involved. There's probably some bagholders. If so, maybe they'll dump it and we can get it cheaper. I added a little at .017 today

A long wants out @ .017 190k impatient

This move very nicely once production orders start coming in

Will take time to develop unless it gets a one day promo like it did in June 2012. Could happen again, the increase in volume since the filing could be frontloading. Hope not, this one now may turn out to be a legitimate one.

Since the 8k of the deal there hasn't been a pop? Hmmm Gem

Since inception the company has only incurred a loss of just over $2 million and all of it can be used as NOL's in future years.

The Company has non-capital loss carry-forwards of approximately $2,279,606 that may be available for tax purposes. The loss carry-forwards are all in respect to U.S. and Australian operations.

Great deal for MLPH..

Under this agreement, following the execution of a licensing deal to a potential partner and/or distribution company in the Territory (DDC Client) during the Term (as defined below) of this agreement, as a result of the Services provided by DDC, DDC will be entitled to receive:

•7% of any capital payment received by MPL immediately upon the sale or licensing of Products or Technology to a DDC Client within the Territory; and

•2% of any periodic payments received by MPL under a product licensing or distribution agreement with a DDC Client within the Territory, net of all costs incurred by MPL in connection with performing its obligations under the respective agreement.

A $87.50 buy moved the 10k ask from .035 to .05. Super thin..

The share structure here has not changed since 2005 when they recapitalized with the acquisition of Molecular Pharmacology (USA) Limited.

Amazing..

Perry Robins endorsing their products will make this a $50-$100+ million market cap stock in the near future imo.

Hiding bids lol..

This dude is backing the MLPH products:

http://www.skincancer.org/about-us/who-we-are/dr-perry-robins

This PPS still has a LONG way to go up imo..

Huge news...

Tripeptofen patents are going to worth HUGE bucks.

This guys backing is just the start IMO.

New 52 week high.

Molecular Pharmacology (USA) Limited

Molecular Pharmacology (USA) Limited is pleased to advise that its wholly-owned subsidiary, Molecular Pharmacology Pty Ltd ( MPL ), an Australian company, has executed an agreement with a New York-based company, Dermatology Development Corporation ( DDC ) to develop and market a range of therapeutic, cosmetic and cosmecutical products based on the ThermaLIFE product range and its active ingredient.

Under the terms of the agreement, DDC is contracted to drive business relationships with a number of third party entities to sell products predominently in the dermatology and cosmetic fields in the US in return for an establishment fee and royalties on the agreements executed as a result of DDC's services, paid for a fixed period net of MPL's costs of sales. The engagement of DDC is limited to the provision of the services in the US, and is for an initial one year period which may be extended by mutual agreement between MPL and DDC.

The signing of this agreement with Professor Perry Robins, M.D. (head of DDC), a high-profile Professor of Dermatology and Chief of the Mohs Micrographic surgery at New York University Medical Center for more than forty years, represents a significant milestone in the expansion of the ThermaLIFE product and its associated technologies, into the US market and the timing is especially important as it coincides with the granting of various patents covering the intellectual property in that territory.

DDC sees this as an opportunity to open up markets in the US for not only the existing product lines but also for the active ingredient to be utilized in new products and creating new business opportunities.

Professor Perry Robins, M.D. is the head of Dermatology Development Corporation and Founder and President of The Skin Cancer Foundation. He is Professor Emeritus of Dermatology and was Chief of the Mohs Micrographic Surgery Unit at New York University Medical Center for more than forty years. He is a pioneer in Mohs Micrographic surgery and has performed more than 40,000 surgical procedures. He is an educator in his field and Dr Robins has trained more than seventy doctors from around the world who are now leaders in dermatologic and skin cancer care.

Dr Robins is also the founder/president of the International Society of Dermatologic Surgery, founder/former president of the American College of Mohs Micrgraphic Surgery and former president of the American Society of Dermatologic Surgery. Dr Robins is an honorary fellow of the American Academy of Dermatology for his outstanding contributions in dermatology and on behalf of The Skin Cancer Foundation he has received numerous Awards for Excellence in Education, Gold Triangle Awards for Excellence in Community Education and a Presidential Citation. He has been honored as a distinguished member of both the American College of Mohs Micrographic Surgery and the American Society of Dermatologic Surgery, and was awarded a Presidential Citation by the International Society of Dermatologic Surgery.


Dr Robins has published over sixty articles in leading medical journals and is the founder of the Journal of Dermatologic Surgery and Oncology . He has authored five books for the general public in addition to his international advancement of his specialty and his commitment to his patients and contribution to education.

See: Current Report Filing (8-k), that's the reason

MLPH is up by 140%

Rather buy MILF than MLPH.

Now that's funny!

Rather buy MILF than MLPH.

Holy buys batman. This thing going to fly...

PharmaNet Group Limited owns 80% of this stock. They are a large biotech company trading on the Aussie exchange..